CB1 receptors play a vital role in regulating various physiological processes such as pain perception, appetite, mood, memory, and motor coordination.

FluoGuide A/S is delighted with the preliminary findings from the FG001 study concerning cancer surgery guidance in head & neck cancer patients.

This article summarized the latest R&D progress of Ipratropium Bromide, the Mechanism of Action for Ipratropium Bromide, and the drug target R&D trends for Ipratropium Bromide.

C5, or the fifth component of complement, plays a crucial role in the human body's immune system.

Tango Therapeutics has received FDA clearance for its IND application for TNG348, a new USP1 inhibitor.

This article summarized the latest R&D progress of Glycopyrrolate, the Mechanism of Action for Glycopyrrolate, and the drug target R&D trends for Glycopyrrolate.

Biotech company Cidara Therapeutics is developing drug-Fc conjugate immunotherapies for serious diseases. Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, has given Cidara a go-ahead for CD388 (JNJ-0953), a universal prevention solution for influenza A and B.

This article summarized the latest R&D progress of Etodolac, the Mechanism of Action for Etodolac, and the drug target R&D trends for Etodolac.

BTK inhibitors can regulate the functions of various immune cells that are crucial to innate and adaptive immune responses.

Guangzhou Gloria Biosciences has announced that Zimberelimab injection (YuTuo®, GLS-010), has received marketing approval from the China NMPA.

This article summarized the latest R&D progress of Dicloxacillin sodium, the Mechanism of Action for Dicloxacillin sodium, and the drug target R&D trends for Dicloxacillin sodium.

BRD4 inhibitors target BRD4 for inhibition, which hold tremendous value in anti-cancer and anti-inflammatory sectors, as well as many other fields.